Introduction: Vedolizumab is a monoclonal antibody that selectively blocks α4β7 integrin and has already been approved for use in patients with moderate-to-severe ulcerative colitis both as first and second line. Etrolizumab is a monoclonal antibody still being tested, which acts with a dual mechanism by selectively inhibiting both α4β7 and αEβ7 integrins.Areas covered: This review provides an overview of the literature data of vedolizumab and etrolizumab, in order to define their role in the treatment of patients with moderate-to-severe ulcerative colitis.Expert opinion: Etrolizumab and vedolizumab block the α4β7 integrin with a similar action mechanism. However, the inhibition of αEβ7 integrin by etrolizumab distinguishes the two anti-integrins making them 'cousin' drugs. Phase 3 clinical trials are needed to confirm the promising etrolizumab's efficacy data and to resolve any doubts about its safety, allowing a clearer comparison with vedolizumab.

中文翻译：

---

Vedolizumab和etrolizumab用于溃疡性结肠炎：双胞胎还是简单的表亲？

简介：维多珠单抗是一种选择性阻断α4β7整联蛋白的单克隆抗体，已经被批准用于中至重度溃疡性结肠炎的一线和二线患者。Etrolizumab是仍在测试中的单克隆抗体，具有通过选择性抑制α4β7和αEβ7整联蛋白来发挥双重作用的作用。研究范围：本综述概述了vedolizumab和etrolizumab的文献数据，以定义它们在治疗中的作用专家意见：Etrolizumab和vedolizumab阻断α4β7整联蛋白的作用机制相似。但是，依特罗珠单抗对αEβ7整联蛋白的抑制作用将两种抗整联蛋白区分为“表兄弟”药物。